Phoenix Biotech Acquisition Corp. Class A (PBAX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CERo is in the running to receive a grant worth $4-6 million from the Cancer Focus Fund at MD Anderson for a clinical trial of its leading drug candidate, CER-1236, aimed at treating acute myeloid leukemia. This funding opportunity, however, comes with no guarantees as it hinges on meeting specific conditions and approvals, with uncertainties still in the mix.
For further insights into PBAX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.